MedPath

Monalizumab

Generic Name
Monalizumab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1228763-95-8
Unique Ingredient Identifier
3ZXZ2V0588
Background

Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.

Associated Conditions
-
Associated Therapies
-

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Phase 2
Not yet recruiting
Conditions
Lung Small Cell Carcinoma, I Subtype
Lung Small Cell Carcinoma, N Subtype
Lung Small Cell Carcinoma, P Subtype
Extensive Stage Lung Small Cell Carcinoma
Lung Small Cell Carcinoma, A Subtype
Interventions
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ceralasertib
Biological: Durvalumab
Drug: Etoposide
Procedure: Magnetic Resonance Imaging
Drug: Platinum Compound
Biological: Monalizumab
Procedure: Positron Emission Tomography
Radiation: Thoracic Radiation Therapy
Drug: Saruparib
First Posted Date
2025-01-10
Last Posted Date
2025-01-10
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
900
Registration Number
NCT06769126

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Phase 1
Active, not recruiting
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma
Locally Recurrent Lung Non-Small Cell Carcinoma
Unresectable Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Interventions
Radiation: Accelerated Hypofractionated Radiation Therapy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Durvalumab
Procedure: Magnetic Resonance Imaging of the Brain with and without Contrast
Biological: Monalizumab
Biological: Oleclumab
Radiation: Radiation Therapy
First Posted Date
2019-01-14
Last Posted Date
2024-12-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
48
Registration Number
NCT03801902
Locations
🇺🇸

MD Anderson in The Woodlands, Conroe, Texas, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇺🇸

MD Anderson West Houston, Houston, Texas, United States

and more 53 locations
© Copyright 2025. All Rights Reserved by MedPath